 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- || JQ-1 / Roche
Review, Journal: Single-cell trajectory analysis reveals a CD9 positive state to contribute to exit from stem cell-like and embryonic diapause states and transit to drug-resistant states. (Pubmed Central) - Aug 5, 2023
Importantly, CD9 knockdown or blockade sensitized SUM149 to JQ1 in vivo by trapping cells in the SCLED state and limiting transit to resistant cell states. Thus, CD9 appears to be critical for the transition from a SCLED state into treatment-resistant cell states and warrants exploration as a therapeutic target in basal-like breast cancer.
- | Journal: A peptide binding to the tetraspanin CD9 reduces cancer metastasis. (Pubmed Central) - Feb 27, 2023
Finally, using a mouse model, we showed that CD9-BP reduced lung metastasis in vivo. These findings provide insight into the mechanism by which CD9-BP inhibits CD9-dependent functions and highlight its potential application as an alternative therapeutic nano-biomaterial for metastatic cancers.
- | Journal: IKKβ increases neuropilin-2 and promotes the inhibitory function of CD9 Bregs to control allergic diseases. (Pubmed Central) - Nov 9, 2022
Our findings delineate a distinct role of IKKβ activation in enhancing Bregs to disturb the immune balance. It identifies Nrp2 as a novel regulatory molecule of Bregs that partly contributes to B cell-mediated immune tolerance.
- | Journal, IO biomarker: Long-chain PUFA ameliorate ETEC-induced intestinal inflammation and cell injury by modulating pyroptosis and necroptosis signaling pathways in IPEC-1 cells. (Pubmed Central) - Dec 20, 2021
Finally, EPA and ARA reduced mRNA expression of fas-associated death domain protein (FADD), caspase 8, receptor interacting protein kinase (RIP) 1, mixed lineage kinase-like protein (MLKL), phosphoglycerate mutase 5 (PGAM5), motility related protein 1 (Drp1) and high mobility protein 1 (HMGB1), and inhibited protein expression of phosphorylated-RIP1 (p-RIP1), p-RIP3, p-MLKL and HMGB1. These data demonstrate that EPA and ARA prevent ETEC K88-induced cell inflammation and injury, which is partly through inhibiting pyroptosis and necroptosis signaling pathways.
- | Journal: CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells. (Pubmed Central) - May 21, 2021
CD9 KO cells were able to compensate the mitochondrial malfunction by increasing total mitochondrial mass reducing mitophagy. Our data thus provide the first evidence for a functional connection of tetraspanin CD9 with mitophagy in melanoma cells.
- | Journal: Cytoskeletal Protein 4.1R Is a Positive Regulator of the FcεRI Signaling and Chemotaxis in Mast Cells. (Pubmed Central) - Nov 19, 2020
The positive regulatory role of 4.1R protein in FcεRI-triggered activation was supported by in vivo experiments in which 4.1R-KO mice showed the normal presence of mast cells in the ears and peritoneum, but exhibited impaired passive cutaneous anaphylaxis. The combined data indicate that the 4.1R protein functions as a positive regulator in the early activation events after FcεRI triggering in mast cells.
- | Journal: Tetraspanin CD9 interacts with α-secretase to enhance its oncogenic function in pancreatic cancer. (Pubmed Central) - Oct 15, 2020
Finally, CD9 antibody showed anti-tumor effects in cell proliferation MTT assay, transwell migration assay and colony formation assay. Our study reveals a novel CD9/ADAM/Notch signaling network in PDAC and it supports that targeting CD9-ADAM interaction with antibody may be a potential therapeutic intervention for PDAC.
- AT1412 / AIMM Therap, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_861;
Legal entity responsible for the study: The authors. Funding: AIMM Therapeutics.